Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Oncology /
      5. B-cell malignancies/
      6. Mantle Cell Lymphoma (MCL)
      B-cell malignancies

      Mantle Cell Lymphoma (MCL)

      June 17, 2024
      1 min read
      • MCL is typically an aggressive, rare form of non-Hodgkin lymphoma that develops from abnormal white blood cells (B-lymphocytes). It is called ‘mantle cell’ because the abnormal lymphocytes come from an area called the ‘mantle zone’ in lymph nodes.[9]
      • The abnormal lymphocytes start to collect in the lymph nodes or body organs. They can then form tumours and begin to cause problems within the lymphatic system or the organ where they are growing.[10]
      • The average incidence rate in Europe is one to two cases per 100,000 people and the median age at diagnosis is approximately 65 years.[11]

      Read more here

      [1] B Cell Metabolism and Autophagy in Autoimmunity - PMC (nih.gov)
      [2]  WebMD. What is B-Cell Lymphoma: Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma#1. Last accessed March 2024.

      [3] National Cancer Institute. Lymphoma-patient version. Available at: https://www.cancer.gov/types/lymphoma. Last accessed March 2024.

      [4] American Cancer Society. What is Chronic Lymphocytic Leukemia? Available at: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html. Last accessed March 2024.

      [5] Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013; 122(23): 3723-27234.

      [6] Chiorazzi M, et al. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.

      [7] Yang O. Trends in disease burden of chronic lymphocytic leukemia at the Global, regional, and national levels from 1990 to 2019, and projections until 2030: A population-based epidemiologic study. Frontiers in Oncology. 2022;12.doi.org/10.3389/fonc.2022.840616.

      [8] Eichhorst B, et al; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23-33.

      [9] Lymphoma Action. Mantle cell lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/mantle-cell-lymphoma. Last accessed March 2024

      [10] Cancer Research UK. Mantle cell lymphoma. Available at: https://cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/mantle-cell. Last accessed March 2024.

      [11] Dreyling M. Newly diagnosed and relapsed mantle cell lymphoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018; 28:iv62–iv71. https://doi.org/10.1093/annonc/mdx223.

      [12] American Cancer Society. What is Waldenstrom Macroglobulinemia? Available at: https://cancer.org/cancer/waldenstrom-macroglobulinemia/about/what-is-wm.html. Last accessed March 2024.

      [13] “Waldenström Macroglobulinemia - Symptoms, Causes, Treatment: Nord. National Organization for Rare Disorders. Available at: https://rarediseases.org/rare-diseases/waldenstroms-macroglobulinemia/. Last accessed March 2024

      [14] Orphanet: Waldenström Macroglobulinemia. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=33226. Last accessed March 2024.

      [15] Lymphoma Action. Diffuse Large B-Cell Lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma. Last accessed March 2024.

      [16] Tilly H. Diffuse Large B-Cell Lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology. 2015; 26: v116–v125. doi:10.1093/annonc/mdv304.

      [17] Smith A. Impact of Age and Socioeconomic Status on Treatment and Survival from Aggressive Lymphoma: A UK Population-Based Study of Diffuse Large B-Cell Lymphoma. Cancer Epidemiology. 2015; 39: 6:1103–1112. doi:10.1016/j.canep.2015.08.015.

      [18] Lymphoma Action. Follicular Lymphoma. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma. Last accessed March 2024.

      [19] Orphanet: Follicular Lymphoma. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=545#:~:text=Clinical%20description,are%20affected%20in%20rare%20cases. Last accessed March 2024.

      [20] Yosifov DY. From biology to therapy: the CLL success story. Hemasphere. 2019;3: e175.

      [21] Schieber M. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7: F1000 Faculty Rev-1136. doi:10.12688/f1000research.14122.1

      [22] Pooja A. Updates in prognostication and treatment of Waldenström’s macroglobulinemia, Hematology/Oncology and Stem Cell Therapy. 2019; 12:4: 179-188. doi.org/10.1016/j.hemonc.2019.05.002. 

      [23] Cheson B D. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal. 2021;11,68.

      [24] Velcade summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf. Last accessed: March 2024.

      [25] Johnson & Johnson. The next frontier of prostate cancer care. Available at: https://www.jnj.com/innovation/next-frontier-prostate-cancer-treatment. Last accessed: March 2024.

      [26] HEAL. Men Prostate Cancer. Available at: https://www.env-health.org/IMG/pdf/prostate_testical.pdf. Last accessed March 2024.

      [27] European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC-White-Paper-Bladder-Cancer-EN-1.pdf. Last accessed March 2024.

      [28] Montazeri K. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1): 1-6.

      [29] Cancer.net. Lung cancer – non-small cell: statistics. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Last accessed March 2024.